MARKET

ORMP

ORMP

Oramed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.91
-0.04
-0.45%
After Hours: 9.59 +0.68 +7.63% 17:22 02/26 EST
OPEN
9.15
PREV CLOSE
8.95
HIGH
9.43
LOW
8.50
VOLUME
340.95K
TURNOVER
--
52 WEEK HIGH
11.71
52 WEEK LOW
2.400
MARKET CAP
237.55M
P/E (TTM)
-13.3643
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Thinking about buying stock in Powerbridge Technologies, BioCryst Pharma, Oramed Pharma, Ampio Pharma, or Plus Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PBTS, BCRX, ORMP, AMPE, and PSTV.
PR Newswire - PRF · 2d ago
Antidiabetics Market Research Report by Manufacturers, Region, Type and Application, Forecast to 2026
Feb 22, 2021 (Heraldkeepers) -- The global antidiabetics market is segmented based on its product which include thiazolodinediones, glp-agonists,...
Heraldkeepers · 6d ago
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17)
Benzinga · 02/18 13:14
Antidiabetics Market Size, by Revenue, Growth Rate and Forecast to 2027 | Novartis, Bayer Corporation, Johnson & Johnson, etc
Market Insight Reports · 02/17 14:13
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 16)
Benzinga · 02/17 12:26
Ladenburg Thalmann & Co. Believes Oramed Pharmaceuticals (ORMP) Won’t Stop Here
Ladenburg Thalmann & Co. analyst Robert LeBoyer maintained a Buy rating on Oramed Pharmaceuticals (ORMP) on January 26 and set a price target of
SmarterAnalyst · 02/17 09:08
Diabetic Ketoacidosis Market Outlook, Industry Demand and Supply, Key Prospects, Pricing Strategies, Forecast and Top Manufacturers Analysis Report
Feb 16, 2021 (Market Insight Reports) -- Technological advancements in diabetic ketoacidosis treatment, significant prevalence of target diseases, and rising...
Market Insight Reports · 02/16 16:03
Antidiabetic Drug Market to see Huge Growth by 2025 | Sanofi-Aventis, Boehringer Ingelheim, Pfizer, AstraZeneca
Feb 16, 2021 (Market Insight Reports) -- Stay up-to-date and exploit latest trends of Antidiabetic Drug Market with latest edition released by AMA....
Market Insight Reports · 02/16 14:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORMP. Analyze the recent business situations of Oramed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ORMP stock price target is 16.83 with a high estimate of 23.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 1.25M
% Owned: 4.68%
Shares Outstanding: 26.66M
TypeInstitutionsShares
Increased
4
16.33K
New
18
-317.98K
Decreased
9
249.68K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Independent Director
Kevin Rakin
Chief Executive Officer/President/Director
Nadav Kidron
Chief Financial Officer/Treasurer/Secretary
Avi Gabay
Chief Financial Officer/Treasurer/Secretary
Avraham Gabay
Chief Operating Officer
Joshua Hexter
Chief Scientific Officer/Director
Miriam Kidron
Independent Director
Aviad Friedman
Independent Director
Xiaoming Gao
Independent Director
Arie Mayer
Independent Director
Leonard Sank
  • Dividends
  • Splits
  • Insider Activity
No Data
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The Company's other product is ORMD-0901, an orally ingestible GLP-1 capsule.

Webull offers kinds of Oramed Pharmaceuticals, Inc. stock information, including NASDAQ:ORMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORMP stock methods without spending real money on the virtual paper trading platform.